Fluoxetine was safe and effective for body dysmorphic disorder.

Patients 74 patients who had DSM-IV confirmed BDD with or without a delusional disorder for ≥ 6 months, were 18–65 years of age, scored ≥ 24 on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS), and scored at least moderate on the Clinical Global Impression scale for BDD (BDD-CGI). Exclusion criteria included psychotic disorder not attributable to delusional BDD, bipolar disorder, alcohol or substance abuse in the previous 6 months, body image concerns better accounted for by an eating disorder, suicide attempt or ideation, recent use of certain psychiatric drugs or psychotherapy, and potential for pregnancy. 67 patients (mean age 32 y, 69% women) were randomised and 59 (88%) completed the trial.